Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study

Arthritis Research and Therapy

Volumn 8, Issue 1, 2005, Pages

  Atzeni, Fabiola ^a   Sarzi Puttini, Piercarlo ^a   Dell' Acqua, Donata ^a   de Portu, Simona ^b   Cecchini, Germana ^c   Cruini, Carola ^c   Carrabba, Mario ^a   Meroni, Pier Luigi ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67349090358     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1851     Document Type: Article

References (49)

1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese C, Wasko MC, Moreland LW, Weaver AW, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
2. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343 1594-1602.
4. Moreland L: Adalimumab in rheumatoid arthritis. Curr Rheumatol Rep 2004, 6:333-334.
5. St Clair EW: Infliximab treatment for Cheumatic disease: clinical and radiological efficacy. Ann Rheum Dis 2002, 61 Suppl 2 ii67-ii69.
6. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFa therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004, 63:1218-1221.
7. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor-α: Findings in open-label and randomised placebo-controlled trials. Arthritis Rheum 2000, 43 2383-2390.
8. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004, 6 R264-R272.
9. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S: Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann Rheum Dis 2005, 64:403-407.
10. De Rycke L, Verhelst X, Kruithof E, Van den Bosh F, Hoffman IE, Veys EM, De Keyser F: Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005, 64:299-302.
11. Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM: Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 2005, 26:58-62.
12. Antivalle M, Marazza MG, Randisi G, Sarzi-Puttini P, Dell'Acqua D, Carrabba M: Longterm treatment of rheumatoid arthritis with infliximab: Efficacy, side effects and autoantibodies induction [abstract]. Arthritis Rheum 2002, 46:s534.
13. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003, 48:1015-1023.
14. Louis M, Rauch J, Armstrong M, Fitzcharles MA: Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003, 30:2557-2562.
15. Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A: Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004, 22:756-758.
16. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: A two-year prospective study. Arthritis Res Ther 2004, 6:R535-R543.
17. Ziolkowska M, Maslinski W: Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol 2003, 15:267-273.
18. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O: Anti-TNFα-induced systemic lupus erythematosus. Clin Rheumatol 2003, 22:56-61.
19. Ferraccioli G, Mecchia F, Di Poi E, Fabris M: Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional comnination therapy: Direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002, 61 358-361.
20. Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannenmark S, Klareskog L, van Vollenhoven RF: Treatment with anti-TNFα antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004, 63 1075-1078.
21. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003, 48:35-45.
22. Burmester GR, Monteagudo Saez I, Malaise M, Canas da Silva J, Webber DG, Kupper H: Efficacy and safety of Adalimumab (HUMIRA) in European Clinical Practice: The ReAct trial. Ann Rheum Dis 2004:s63. [abstract]
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
24. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993, 20:579-581.
25. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
26. Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, Porenta-Besic V, Cecchini G, Borghi MO, Meroni PL: Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61 608-611.
27. Bayer PM, Bauerfeind S, Bienvenu J, Fabien N, Frei PC, Gilburd B, Heide KG, Hoier-Madsen M, Meroni PL, Monier JC, et al.: Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. J Autoimmun 1999, 13:89-93.
28. Fritzler MJ: New technologies in the detection of autoantibodies evaluation of addressable laser bead immunoassays (ALBIA). In Autoantigens, Autoantibodies, Autoimmunity Volume 4. Edited by: Conrad K, Bachmann MP, Chan EKL, Fritzler MJ, Humbel RL, Sack U, Shoenfeld Y. Berlin: Pabst Science Publishers; 2004:449-462.
29. Riboldi P, Gerosa M, Moroni G, Radice A, Sinico A, Tincani A, Meroni PL: Anti-DNA antibodies: A diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 2005, 38:39-45.
30. Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC: Anticardiolipin antibody assay: A methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001, 86:575-583.
31. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ: Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002, 46:906-912.
32. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163.
33. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL: The prognostic value of anti-cyclic cit rullinated peptide antibodies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43:1831-1835.
34. Meyer O, Labarre C, Dougados M, Goupilee P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B: Anti-citrullinated protein/ peptide antibody assay in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003, 62:120-126.
35. Bas S, Genevay S, Metyer O, Gabay C: Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:677-680.
36. van Venrooij WJ, Hazes JM, Visser H: Anticitrullinated protein/ peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002, 60:383-388.
37. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT: The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis Ann Rheum Dis in press.
38. Yazdani-Biuki B, Standlmainer E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, Mueller T, Brickmann K, Graninger WB, Brezinschek HP: Blockade of tumor necrosis factor α significantly alters the serum levels of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:1224-1226.
39. Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM: Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004, 50:3776-3782.
40. Furst DE: Rational use of disease-modifying antirheumatic drugs. Drugs 1990, 39:19-37.
41. 2+- dependent deimination induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain. J Biol Chem 1989, 264:18119-18127.
42. Lugering A, Schmidt M, Lugering N, Pauels HG, Domaschke W, Kucharzik T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
43. Keystone E, Haraoui B: Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am 2004, 30:349-364.
44. Keane A, Woods R, Dowding V, Roden D, Barry C: Anticardiolipin antibodies in rheumatoid arthritis. Br J Rheumatol 1987, 26 346-350.
45. Wolf P, Gretler J, Aglas F, Auer-Grumbach P, Rainer F: Anticardiolipin antibodies in rheumatoid arthritis: Their relation to rheumatoid nodules and cutaneous vascular manifestations. Br J Dermatol 1994, 131:48-51.
46. Casciola-Rosen L, Rosen A, Petri M, Schlissel M: Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996, 93 1624-1629.
47. Price BE, Rauch J, Shia MA, Walsh MT, Lieberthal W, Gilligan HM, O'Laughlin T, Koh JS, Levine JS: Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996, 157:2201-2208.
48. D'Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, Sabbadini MG: Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 2004, 255:409-418.
49. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD: In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001, 167 6821-6826.